{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:58:42Z","timestamp":1760237922831,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Neutropenia and febrile neutropenia are common and potentially life-threating events associated with chemotherapy treatment in Hodgkin lymphoma (HL). Neutropenia-related infectious events could be an issue both for direct clinical consequences and for delay in treatment delivery, affecting final outcomes in a potentially highly curable disease. Pegfilgrastim is the pegylated form of filgrastim, the recombinant form of human G-CSF, capable of prevent and mitigate neutropenic effects of chemotherapy, when adopted as primary prophylaxis in several hematological malignancies. No updated version of major international guidelines provides clear indication on prophylaxis use of pegfilgrastim in HL to prevent febrile neutropenia episodes in HL. Moreover, to date, scarce and non-uniform clinical experiences evaluating pegfilgrastim as prophylaxis in HL are present in the literature. Herein, we propose a brief summary of the literature data about efficacy and safety of the use of pegfilgrastim as primary prophylaxis in HL during chemotherapy treatment.<\/jats:p>","DOI":"10.3390\/cancers14174063","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T21:05:12Z","timestamp":1661288712000},"page":"4063","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pegfilgrastim in Supportive Care of Hodgkin Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"first","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-5875","authenticated-orcid":false,"given":"Davide","family":"Nappi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Bone Marrow Transplantation (CBMT), Ospedale Centrale di Bolzano, 39100 Bolzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-4433","authenticated-orcid":false,"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, Haematology Section, University of Catania, 95123 Catania, Italy"},{"name":"Division of Haematology, AOU Policlinico \u201cVittorio Emanuele\u201d, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00520-016-3277-0","article-title":"Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies","volume":"24","author":"Li","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal Management of Neutropenic Fever in Patients with Cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","article-title":"Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)","volume":"96","author":"Heinz","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3536(96)80018-7","article-title":"The epidemiology of Hodgkin\u2019s disease","volume":"9","author":"Glaser","year":"1996","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2165\/00003495-199142020-00009","article-title":"Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions","volume":"42","author":"Hollingshead","year":"1991","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1634\/theoncologist.10-2-138","article-title":"Increasing chemotherapy dose density and intensity: Phase I trials in non-small cell lung cancer and non-Hodgkin\u2019s lymphoma","volume":"10","author":"Blayney","year":"2005","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1200\/JCO.2002.12.113","article-title":"Dose-dense anthracycline-based chemotherapy for node-positive breast cancer","volume":"20","author":"Ellis","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2004.04.004","article-title":"Dose-dense chemotherapy in breast cancer and lymphoma","volume":"31","author":"Hudis","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.1989.7.10.1554","article-title":"Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy","volume":"7","author":"Morstyn","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.40.4.988","article-title":"Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts","volume":"40","author":"Takatani","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.45.7.1947-1951.2001","article-title":"Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients","volume":"45","author":"Fukuda","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim","volume":"50","author":"Yang","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_21","first-page":"1028","article-title":"Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity","volume":"20","author":"Malik","year":"1992","journal-title":"Exp. Hematol."},{"key":"ref_22","first-page":"A918","article-title":"Ex Vivo Half-Life of Neutrophils from Healthy Human Subjects Pre and Post Treatment with Daily Filgrastim or Single-Dose Pegfilgrastim","volume":"100","author":"Allen","year":"2002","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/1042819031000103953","article-title":"Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma","volume":"44","author":"Grigg","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00520-016-3468-8","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: A single center, real-life experience","volume":"25","author":"Cerchione","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00520-020-05982-0","article-title":"Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: Real-world, single-center experience","volume":"29","author":"Moore","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1007\/s00520-021-06045-8","article-title":"Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin\u2019s lymphoma","volume":"29","author":"Roder","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","article-title":"Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma","volume":"21","author":"Vose","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.14088","article-title":"A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma","volume":"174","author":"Kubo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.3324\/haematol.2018.196782","article-title":"Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD","volume":"103","author":"Villa","year":"2018","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: Risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.ejca.2006.07.012","article-title":"Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma","volume":"42","author":"Younes","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/bjc.2013.605","article-title":"A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity","volume":"109","author":"Gibb","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_35","first-page":"546","article-title":"Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin\u2019s lymphoma: Results of a phase II study","volume":"91","author":"Engert","year":"2006","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.2003.06.028","article-title":"14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin\u2019s lymphoma: Results of a pilot study of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Sieber","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00520-014-2490-y","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: A real-life experience","volume":"23","author":"Cerchione","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1007\/s00520-016-3430-9","article-title":"Managing neutropenia by pegfilgrastim in patients affected by relapsed\/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone","volume":"24","author":"Cerchione","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00520-019-4651-5","article-title":"Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies-bendamustine and G-CSF support","volume":"27","author":"Cerchione","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3816\/CBC.2003.n.003","article-title":"Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer","volume":"3","author":"Kubista","year":"2003","journal-title":"Clin. Breast Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","article-title":"Prevention of pegfilgrastim-induced bone pain: A phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base","volume":"30","author":"Kirshner","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:48Z","timestamp":1760141628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14174063"],"URL":"https:\/\/doi.org\/10.3390\/cancers14174063","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,8,23]]}}}